Genmab gets latest milestone in daratumumab Janssen collaboration

Danish biotech company Genmab (OMX: GEN) has reached the fourth milestone in its daratumumab collaboration with US health care giant Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen.

The $10 million payment was triggered by progress in the ongoing Phase III study of daratumumab in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone, in the treatment of relapsed or refractory multiple myeloma.

Jan van de Winkel, chief executive of Genmab, said: “We are very pleased with the firm progress being made in the daratumumab development program under the direction of our strategic partner Janssen. At Genmab we are committed to developing differentiated therapeutics to fight cancer, and it is therefore rewarding to see one of our antibodies moving rapidly through clinical development.”